Page 108 - Haematologica August 2018

C. Melani et al. References
1. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851-862.
2. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B- cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102(12):3871-3879.
3. Bishop PC, Wilson WH, Pearson D, Janik J, Jaffe ES, Elwood PC. CNS involvement in primary mediastinal large B-cell lym- phoma. J Clin Oncol. 1999;17(8):2479- 2485.
4. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408-1416.
5. Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol. 2011;22(3):664-670.
6. Xu LM, Fang H, Wang WH, et al. Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiv- ing doxorubicin-containing chemotherapy. Leuk Lymphoma. 2013;54(8):1684-1690.
7. Vassilakopoulos TP, Pangalis GA, Katsigiannis A, et al. Rituximab, cyclophos- phamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lym- phoma: the emerging standard of care. Oncologist. 2012;17(2):239-249.
8. Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for pri- mary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica. 2002;87(12):1258-1264.
9. Soumerai JD, Hellmann MD, Feng Y, et al. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophos- phamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma. 2014;55(3):538-543.
10. Binkley MS, Hiniker SM, Wu S, et al. A sin- gle-institution retrospective analysis of out- comes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. Leuk Lymphoma. 2016;57(3): 604-608.
11. van Leeuwen FE, Ng AK. Long-term risk of second malignancy and cardiovascular dis- ease after Hodgkin lymphoma treatment.
Hematology Am Soc Hematol Educ
Program. 2016;2016(1):323-330.
12. Bhakta N, Liu Q, Yeo F, et al. Cumulative burden of cardiovascular morbidity in pae- diatric, adolescent, and young adult sur- vivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study.
Lancet Oncol. 2016;17(9):1325-1334.
13. Sud A, Thomsen H, Sundquist K, Houlston RS, Hemminki K. Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History. J Clin Oncol.
2017;35(14):1584-1590.
14. Schaapveld M, Aleman BM, van
Eggermond AM, et al. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. N Engl J Med. 2015;373(26):2499-2511.
15. Pinnix CC, Dabaja B, Ahmed MA, et al. Single-institution experience in the treat- ment of primary mediastinal B cell lym- phoma treated with immunochemothera- py in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015;92(1):113-121.
16. Russo F, Corazzelli G, Frigeri F, et al. A phase II study of dose-dense and dose- intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma. Br J Haematol. 2014;166(1):118-129.
17. Raemaekers JM, Andre MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32(12):1188-1194.
18. Wolden SL, Chen L, Kelly KM, et al. Long- term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group. J Clin Oncol. 2012;30(26):3174-3180.
19. Cheah CY, Hofman MS, Seymour JF, et al. The utility and limitations of (18)F-fluo- rodeoxyglucose positron emission tomog- raphy with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. Leuk Lymphoma. 2015;56(1):49-56.
20. Filippi AR, Piva C, Giunta F, et al. Radiation therapy in primary mediastinal B-cell lym- phoma with positron emission tomogra- phy positivity after rituximab chemothera- py. Int J Radiat Oncol Biol Phys. 2013;87(2):311-316.
21. Vassilakopoulos TP, Pangalis GA, Chatziioannou S, et al. PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analy- sis of 106 patients regarding prognostic sig-
nificance and implications for subsequent radiotherapy. Leukemia. 2016;30(1):238- 242.
22. Martelli M, Ceriani L, Zucca E, et al. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary medi- astinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol. 2014;32(17):1769-1775.
23. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.
24. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consen- sus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048-3058.
25. Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99(8):2685-2693.
26. Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009;50(8):1257-1260.
27. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association. 1958;53(282):457-481.
28. Shah NN, Szabo A, Huntington SF, et al. R- CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediasti- nal B-cell lymphoma: a multi-centre analy- sis. Br J Haematol. 2018;180(4):534-544.
29. Kuruvilla J, Pintilie M, Tsang R, Nagy T, Keating A, Crump M. Salvage chemothera- py and autologous stem cell transplantation are inferior for relapsed or refractory pri- mary mediastinal large B-cell lymphoma compared with diffuse large B-cell lym- phoma. Leuk Lymphoma. 2008;49(7):1329- 1336.
30. Ceriani L, Martelli M, Zinzani PL, et al. Utility of baseline 18FDG-PET/CT func- tional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood. 2015;126(8):950-956.
31. Ceriani L, Martelli M, Conconi A, et al. Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18- FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study. Br J Haematol. 2017;178(4):588-591.
32. Giulino-Roth L, O'Donohue T, Chen Z, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol. 2017;179(5):739-747.
1344
haematologica | 2018; 103(8)